دراسة تربط أدوية GLP-1 بخطر طفيف لتساقط الشعر

24 يوليو، 2026

من إعداد الذكاء الاصطناعي

كشف تحليل جديد لسجلات المرضى أن البالغين المصابين بداء السكري من النوع الثاني الذين يتناولون ناهضات مستقبلات GLP-1 يواجهون معدلاً أعلى للإصابة بالثعلبة مقارنة بمن يتناولون أدوية أخرى شائعة لمرض السكري.

فحصت الدراسة، التي نُشرت في 22 يوليو 2026 في دورية The BMJ، السجلات الصحية الإلكترونية من Penn Medicine والتي تغطي المرضى الذين عولجوا في الفترة من يناير 2019 إلى سبتمبر 2024.

بعد إجراء تعديلات على أساس العمر والجنس ومؤشر كتلة الجسم وعوامل أخرى، أظهر مستخدمو أدوية GLP-1 خطراً أعلى بنسبة 37 بالمائة للإصابة بالثعلبة مقارنة بمستخدمي مثبطات SGLT-2، وخطراً أعلى بنسبة 68 بالمائة مقارنة بمستخدمي مثبطات DPP-4.

اقتصر الخطر المتزايد على الثعلبة غير الندبية، وهي حالة قد تسمح بنمو الشعر مجدداً. وظلت المعدلات المطلقة منخفضة عند حوالي 6 إلى 7 حالات لكل 1000 شخص في السنة.

وأشار الباحثون إلى أن فقدان الوزن السريع المرتبط بهذه الأدوية قد يسهم في هذا التأثير من خلال نقص المغذيات أو التحولات الهرمونية، على الرغم من أن الدراسة لم تستطع تأكيد وجود علاقة سببية.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

21 مايو، 2026 من إعداد الذكاء الاصطناعي صورة مولدة بواسطة الذكاء الاصطناعي تم التحقق من الحقائق

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

8 مايو، 2026 من إعداد الذكاء الاصطناعي تم التحقق من الحقائق

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

Technology

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Health

Trojan horse obesity drug boosts weight loss in mice

Health

Study links Ozempic to lower depression and anxiety risks

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

Researchers say genetic variants in the PAM gene may help explain why some people with Type 2 diabetes get less blood-sugar benefit from GLP-1 receptor agonist drugs such as Ozempic, a phenomenon they describe as “GLP-1 resistance.”

Rutgers study finds GLP-1 drug use is tied to a weaker link between impulsivity and self-reported violence

17 يونيو، 2026 من إعداد الذكاء الاصطناعي تم التحقق من الحقائق

A study from Rutgers University reports that adults currently using GLP-1 receptor agonist medications—including semaglutide brands Ozempic and Wegovy—showed a substantially weaker association between impulsivity and self-reported violent behavior than former users. The research, published June 17, 2026 in the journal Criminology, was based on a 2025 U.S. survey and does not establish cause and effect.

Stanford scientists report appetite-suppressing peptide that reduced weight in mice and pigs

Stanford Medicine researchers say they have identified a naturally occurring 12–amino-acid peptide, BRP, that suppressed appetite and reduced body weight in animal studies. The team used a computational tool dubbed “Peptide Predictor” to identify the molecule, and reported that BRP produced anti-obesity effects in mice and minipigs without signs of nausea- or aversion-like responses seen with some GLP-1–based drugs.

26 يوليو 2026 00:20

دراسة تربط أدوية GLP-1 بخطر طفيف لتساقط الشعر

مقالات ذات صلة

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Oral GLP-1 pill shows strong results in diabetes trial

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

Trojan horse obesity drug boosts weight loss in mice

Study links Ozempic to lower depression and anxiety risks

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

Rutgers study finds GLP-1 drug use is tied to a weaker link between impulsivity and self-reported violence

Stanford scientists report appetite-suppressing peptide that reduced weight in mice and pigs

Oral GLP-1 drugs reduce food reward signals in mice

High costs limit access to GLP-1 weight loss drugs

Semaglutide dosing mistakes fuel rise in poison control calls

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

Study presented at ENDO 2026 links semaglutide to fewer fractures in people with type 2 diabetes

Claims-data study finds many people with type 2 diabetes restart GLP-1 drugs after stopping

Study: Physical activity fell after some patients with obesity started GLP-1 drugs

Study links GLP-1 drugs to lower breast cancer risk

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

Study finds people who use Ozempic-like drugs for weight loss face added stigma

يستخدم هذا الموقع ملفات تعريف الارتباط